Start a live chat
1-800-870-4800
How NMN went from
obscure biochemistry
to the center of longevity thinking.
Nicotinamide mononucleotide did not arrive in longevity biology suddenly. It was uncovered slowly — through decades of foundational work on cellular energy, a pivotal connection between a family of aging-related proteins and a molecule they could not function without, and a sequence of animal findings compelling enough to seed one of the most active areas of human aging biology today.
I
A molecule hiding
in plain biochemical sight.
For most of the twentieth century, nicotinamide mononucleotide was not a subject of longevity interest. It was a known molecule — documented in the biochemistry literature as an intermediate in NAD+ biosynthesis — but its significance was understood only in the narrow metabolic terms of cellular energy chemistry. It was a step in a pathway, not a subject in its own right. The idea that it might be relevant to aging would have seemed, to most biochemists of that era, like an odd category error.
What changed was not the molecule. What changed was the understanding of what NAD+ does beyond energy metabolism — and specifically, the discovery that a family of proteins whose activity was associated with lifespan in simple organisms required NAD+ to function at all. That discovery reframed NAD+ from a metabolic cofactor into something far more consequential: a molecule whose availability appeared to be connected, through a set of enzymes now understood to govern critical cellular maintenance processes, to the biology of aging itself.
Once that reframing happened, everything upstream of NAD+ — including NMN — took on new significance. If NAD+ mattered to aging biology, and if NAD+ declined with age, then the molecules the body used to produce NAD+ became objects of intense interest. NMN, as the most direct precursor in the dominant adult biosynthesis pathway, moved from biochemical footnote to central character. The journey from there to where the field stands today is one of the more instructive stories in contemporary longevity science — and understanding it is part of understanding what NMN is and why it matters.
What changed was not the molecule.
What changed was the understanding
of everything NAD+ was doing
that no one had noticed yet.
Two Eras of Understanding
How the view of NAD+ —
and NMN — fundamentally shifted.
NAD+ as metabolic bookkeeping. NMN as a minor intermediate.
NAD+ understood primarily as an electron carrier in energy metabolism
Its role limited, in most frameworks, to glycolysis and the citric acid cycle
NMN recognized as a biosynthetic intermediate — a step, not a subject
No connection established between NAD+ levels and the rate of biological aging
Sirtuins known in yeast but not yet understood as NAD+-dependent regulators
The idea of NMN as a longevity-relevant molecule essentially absent from biology
NAD+ as a master regulator. NMN as its most direct precursor.
NAD+ understood as the substrate governing sirtuins, PARPs, and CD38
Its decline with age identified as a driver — not merely a marker — of cellular aging
NMN recognized as the terminal Salvage Pathway precursor — one step from NAD+
Age-related NAD+ decline documented across multiple tissues in mammals
NMN administration in aged animals shown to influence multiple biological systems
Human clinical trials of NMN underway — pharmacokinetics confirmed, biology being mapped
II
The four moments
that changed everything.
The arc from NMN as biochemical footnote to NMN as longevity supplement was not a single discovery. It was a sequence of conceptual shifts — each building on the last, each opening a question that the next answered — that unfolded across roughly four decades of biology. Understanding those shifts is the clearest way to understand why NMN occupies the position it does today.
The first shift was the identification of sirtuins — a family of proteins conserved from yeast to mammals — as lifespan regulators in simple organisms, and the subsequent discovery that their enzymatic activity required NAD+ as a substrate. This single finding transformed NAD+ from a metabolic molecule into a potential determinant of biological aging. If the enzymes that extended lifespan in yeast consumed NAD+ to do their work, then the availability of NAD+ in a cell was not just a question of energy chemistry. It was a question of how well the cellular maintenance systems that sirtuins governed could actually function.
The second shift was the documentation of NAD+ decline with age — first in animal models, then in human tissue studies — and the identification of the mechanisms driving it. NAMPT activity falling. CD38 expression rising. The compounding of reduced production with accelerated degradation across the decades of adult life. This gave the first shift its urgency: not only did NAD+ govern sirtuin function, but the body was progressively less capable of maintaining adequate NAD+ as it aged.
The third shift was the demonstration that NMN could restore NAD+ levels in aged animal tissue — and that doing so appeared to influence biological markers across multiple organ systems simultaneously. This was the moment when NMN moved from a theoretical interest to an active research focus. The fourth, still unfolding, is the translation of those animal findings into human biology through the clinical trials now producing data. Each shift changed what the next question had to be.
Four Turning Points
The conceptual shifts that moved
NMN to the center of longevity biology.
Turning Point 01
Sirtuins require NAD+ — and sirtuins govern aging
The foundational insight that transformed NAD+ from a metabolic molecule into a longevity-relevant one: the protein family associated with lifespan extension in yeast, and later in other organisms, was found to be NAD+-dependent. Without adequate NAD+, sirtuins cannot perform the deacylation reactions that regulate gene expression, coordinate DNA repair, and govern the cellular stress response. This created the direct mechanistic link between NAD+ availability and the function of the body's most studied longevity-associated enzyme family.
Turning Point 02
NAD+ declines with age — and the mechanisms are identifiable
The documentation of age-related NAD+ decline in mammalian tissue, alongside the identification of NAMPT decline and CD38 rise as its primary drivers, gave the sirtuin connection its practical dimension. It was no longer simply that NAD+ governed important biology. NAD+ was being systematically depleted by the normal process of aging — which meant that the biology NAD+ governed was being progressively compromised in every aging body, not just in experimental conditions designed to test the hypothesis.
Turning Point 03
NMN restores NAD+ in aged animals — with broad biological effects
The demonstration that NMN administration in aged mice restored NAD+ levels and influenced biological markers across multiple systems — energy metabolism, muscle function, eye function, bone density, immune markers — was the moment that made NMN a research priority rather than a theoretical interest. The breadth of effects suggested that NAD+ restoration was not simply correcting one pathway but was influencing the broader cellular maintenance landscape that NAD+ availability governs. This seeded the human research programs now underway.
Turning Point 04
Human pharmacokinetics confirmed — the clinical era begins
The publication of first-in-human safety and pharmacokinetic data for NMN — confirming that orally administered NMN was absorbed, converted to NAD+ metabolites in the bloodstream, and well-tolerated — opened the clinical era. Human trials are now examining NMN across cardiovascular aging, metabolic health, skeletal muscle function, cognitive biology, and epigenetic age markers. The fourth turning point is still in motion, and the data it produces will determine how the story of NMN and NAD+ in human longevity biology is ultimately written.
The Arc in Brief
From energy chemistry
to longevity biology — in decades.
NAD+ characterized as an electron carrier — essential but narrowly understood
Early biochemistry establishes NAD+ (then called coenzyme I or DPN) as a central player in cellular energy metabolism — accepting electrons during glycolysis and the citric acid cycle. Its role is understood in metabolic terms only. NMN is documented as a biosynthetic intermediate. No connection to aging exists in the literature.
Sir2 identified as NAD+-dependent — and connected to lifespan in yeast
Landmark work establishes that Sir2 — the founding sirtuin — requires NAD+ for its deacetylase activity and that its expression extends lifespan in yeast. This is the pivotal conceptual moment: NAD+ is no longer just a metabolic molecule. It is a substrate whose availability governs the activity of a lifespan-associated protein. The question of what this means in mammals becomes the next decade's central preoccupation.
NAMPT identified, NAD+ decline documented in aging mammals, NMN shown to restore it
A decade of accelerating discovery: NAMPT is identified as the rate-limiting enzyme in the mammalian Salvage Pathway. Age-related NAD+ decline is documented across multiple tissues. NMN administration in aged mice is shown to restore NAD+ levels and influence biological markers across energy metabolism, muscle, bone, eye, and immune function. The animal case for NMN as a longevity-relevant molecule becomes compelling enough to justify human investigation.
First human safety data published — clinical trials multiply across aging biology domains
Human pharmacokinetic studies confirm NMN is absorbed orally and converted to NAD+ metabolites in the bloodstream. Clinical trials expand across multiple institutions and countries, examining NMN in the context of cardiovascular aging, metabolic health, muscle biology, cognitive function, and epigenetic age clocks. The human chapter is the most recent and most actively evolving part of the NMN story — with new findings continuing to emerge as this series is being written.
The Scale of the Story
What the arc of NMN biology
looks like in numbers.
~80
Years from NAD+'s initial biochemical characterization to its identification as a longevity-relevant molecule
The gap between NAD+'s discovery as an electron carrier in the 1930s and the sirtuin-NAD+ connection of the late 1990s spans roughly eighty years — a reminder that the most consequential biological insights often arrive long after the molecule is first described. NMN was present in the biochemistry literature for decades before the framework existed to understand why it mattered.
7
Mammalian sirtuins identified — all NAD+-dependent — governing processes from DNA repair to circadian rhythm
The expansion from a single yeast sirtuin to a family of seven mammalian enzymes, each with distinct tissue distribution and biological functions, revealed the true breadth of the NAD+-longevity connection. It was no longer one protein in one organism. It was a conserved family governing cellular maintenance across the body — all of them requiring the molecule that aging progressively depletes.
20+
Human clinical trials of NMN registered or published since the first human safety data appeared in 2019
The speed with which the human research on NMN has expanded — from near-zero clinical data before 2019 to more than twenty registered or published trials within a few years — reflects the scientific community's assessment of the strength of the preclinical case. Few molecules have moved from animal models to this volume of human research this quickly in the longevity biology field.
III
Where the story stands —
and what it means for how NMN is understood today.
The journey of NMN from biochemical intermediate to the center of longevity biology is not a story that is finished. It is a story in the middle of its most consequential chapter — the one where the compelling biology established in animal models either translates to human aging or reveals the limits of that translation. The human clinical data is still accumulating, and the full picture of what NMN means for human longevity will be written by the trials now running, not by the animal literature that preceded them.
What the historical arc provides is not a guarantee of outcome. It provides a foundation — a mechanistic story so detailed, so consistently replicated across organisms and tissues, and so firmly grounded in the basic chemistry of how cells maintain themselves, that the human investigation it has seeded represents a serious scientific program rather than a commercial trend. NMN is studied not because it is fashionable but because the biology of NAD+, sirtuins, and cellular aging provides a genuinely coherent rationale for studying it.
That coherence is what the Codeage approach to Cellular Longevity is grounded in — a molecule with a traceable biological story, a documented mechanism of age-related decline, and an active human research program working to establish its significance. The science here is still developing, and what this field understands today will be refined and expanded by the work being done right now. For the full picture of how NMN fits into the cellular biology of NAD+ decline, the aging and NAD+ article and the biosynthesis story cover the underlying mechanisms in full.
NMN is studied not because
it is fashionable —
but because the biology that
surrounds it is genuinely coherent.
Codeage · Pillar 03 · Cellular Longevity
Built for the
cellular long game.
Cellular Longevity is Pillar 03 of The Longevity Code — the dimension of the system built around NAD+ biology, mitochondrial health, and the science of cellular aging.
Explore Cellular Longevity →
